Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
tyrosine kinase inhibitors
Pharma
Dizal's Zegfrovy adds more pressure to J&J's Rybrevant
The success of the Wu-Kong28 study shows Zegfrovy's potential as the first oral, chemo-free regimen in first-line EGFR exon 20-mutated NSCLC.
Angus Liu
Mar 23, 2026 10:25am
Exelixis aims to be a top 5 solid tumor drugmaker in the US: CEO
Jan 16, 2026 1:00pm
Pfizer scores again in HER2-positive breast cancer
Oct 14, 2025 12:33pm
With lung cancer FDA nod, it's David versus Goliath
Jun 11, 2025 4:17pm
JPM25: Takeda touts 6 pipeline assets with big sales potential
Jan 15, 2025 3:17pm
ASCO: Bristol calls Roche and AZ's bets in 1L liver cancer
Jun 4, 2024 8:00am
